Wugen is a clinical-stage biotechnology company developing allogeneic, off-the-shelf cellular therapies for cancer.

Wugen

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

Apple Mobile Web Clips Icon

Google Font API

WordPress

Font Awesome

Organization Schema

reCAPTCHA

Sitelinks Search Box

Chief Operating Officer, Executive Vice President of Research & Development

Ayman Kabakibi

President & Chief Executive Officer

Daniel Kemp

Chief Medical Officer

Jan Davidson

Co-Founder & Chief Scientific Officer​

Matthew Cooper

Operations

Eileen McNulty

Vice President R&D Project Management

Karen Mullis

Vice President of CMC

Kenneth Chrobak

Vice President, Finance and Business Operations

Mark Lewis

Vice President, Product Development & Leadership

Monika Sharma

VP & Head, NK Research

Ryan Sullivan

Peter Kiener

Bosun Hau

Bali Muralidhar

Dan Kemp

John McKearn

Keith Vendola

CHIEF EXECUTIVE OFFICER AND PRESIDENT

Kumar Srinivasan

Co-Founder and Chief Scientific Officer

United States Companies With More Than 50 Employees (Top 10K)

Startups Founded in 2018 (Top 10K)

St Louis Startups

Companies With Less Than $50M in Revenue (Top 10K)

Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cell malignancies.

Abingworth

Tybourne Capital Management

Series B - Wugen

Seed Round - Wugen

St Louis

Missouri

United States

North America

Phase 2 Findings Show Wugen's Investigational Allogeneic

St. Louis firm, backed by $200M in funding, gets regulatory nods to 'expedite' review of cancer drug - St. Louis Business ...

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to ...

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Register Stunning Growth by 2032, Predicts ...

Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen's Off-the-shelf CAR-T Cellular ...

Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer

NK Cell Therapy Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

An allogeneic memory NK cell therapy designed to treat a variety of hematologic malignancies and solid tumors by enhancing anti-tumor response and cytokine production.

An allogeneic CAR-T cell therapy targeting CD7 for the treatment of T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma, designed to prevent fratricide and reduce the risk of Graft vs. Host Disease.

A platform for generating memory NK cells without feeder cells, which are cryopreserved for off-the-shelf use in cancer treatment.

A platform for engineering CAR-T cells from healthy donors by deleting target antigens and T-cell receptors to prevent self-killing and Graft vs. Host Disease.

United Kingdom

Europe

Germany

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 19, 2024 1:52 PM	e2aede40
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 1:52 PM	17439602
crunchbase trigger	general	Nov 19, 2024 1:52 PM	b34c058d
crunchbase profile	general	Nov 20, 2024 10:44 AM	2dda4390
li profile	general	Nov 19, 2024 1:52 PM	d718fb28
translate crunchbase fundingrounds	general	Nov 20, 2024 11:07 AM	12fb129b
peers	general	Nov 19, 2024 1:52 PM	27b8b947
news basic	general	Nov 19, 2024 1:52 PM	90f5780c
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

WUGE

COM:WUGEN

Wugen